Tag: tofacitinib

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

| December 1, 2019

J Clin Aesthet Dermatol. 2019;12(12):28–34 by Corinna E. Psomadakis, MBBS, and George Han, MD Drs. Psomadakis and Han are with the Department of Dermatology, Mount Sinai Medical Center in New York, New York. FUNDING: No funding was provided for this study. DISCLOSURES: Dr. Han has consulted for Regeneron, Sanofi Genzyme, Pfizer, Sun, and Janssen. Dr. […]

Continue Reading

Letters to the Editor: Long-term Treatment with Tofacitinib in Severe Alopecia Areata: An Update

Letters to the Editor: Long-term Treatment with Tofacitinib in Severe Alopecia Areata: An Update

| June 1, 2019

Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. An increasing number of studies have demonstrated the efficacy of tofacitinib in treatment of alopecia areata (AA).1–6 Treatment duration in these studies […]

Continue Reading